(Albany, US) DelveInsight has launched a new report on Alzheimer’s disease Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Alzheimer’s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer’s disease (AD) market share of the individual therapies, current and forecasted Alzheimer’s disease (AD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer’s disease (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases. The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty remembering newly learned information because Alzheimer’s changes typically begin in the part of the brain that affects learning.
Request for :- free sample page
Epidemiology
The Alzheimer’s disease (AD) epidemiology division provide insights about historical and current Alzheimer’s disease (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Report key facts:-
1. According to a review article entitled “Alzheimer Disease” by LianaG.Apostolovaet al., one nationally representative US data set, the Aging, Demographics, and Memory Study (ADAMS), estimated that in the United States, 14% of people of 71 years and older have dementia. Alzheimer’s Disease (AD) accounted for 70% of the dementia cases across the age spectrum in this cohort [2016].
2. AlzheimerEuropeestimates the number of people with dementia in Germany in 2012 as being 1.92% of the total population. The number of people with dementia as a percentage of the population is somewhat higher than the EU average of 1.55%.
3. According to Alzheimer’s Association, the percentage of people with Alzheimer’s dementia increases with age: <5% of people aged 65-74, <20% of people aged 75-84, and >30% and <50% of people aged 85 and older have Alzheimer’s dementia. Out of these more than 50% are aged 75 or older [2018]
Key companies are working on this disease that are given below:-
1. Lohmann Therapie- Systeme/ Novartis Pharma Co.
2. Green Valley Pharmaceuticals.
3. AgeneBio
Name of drugs covered are given below:-
1. Exelon
2.Oligomannate
3. AGB101
1. Key Insights
2. Executive Summary of Alzheimer’s disease (AD)
3. Competitive Intelligence Analysis for Alzheimer’s disease (AD)
4. Alzheimer’s disease (AD): Market Overview at a Glance
4.1. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2017
4.2. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2030
5. Alzheimer’s disease (AD): Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Alzheimer’s disease (AD) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Alzheimer’s disease (AD) Treatment and Management
8.2. Alzheimer’s disease (AD) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Alzheimer’s disease (AD) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Alzheimer’s disease (AD): Seven Major Market Analysis
13.1. Key Findings
13.2. Alzheimer’s disease (AD) Market Size in 7MM
13.3. Alzheimer’s disease (AD) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Alzheimer’s disease (AD) Total Market Size in the United States
15.1.2. Alzheimer’s disease (AD) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Alzheimer’s disease (AD) Total Market Size in Germany
15.3.2. Alzheimer’s disease (AD) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Alzheimer’s disease (AD) Total Market Size in France
15.4.2. Alzheimer’s disease (AD) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Alzheimer’s disease (AD) Total Market Size in Italy
15.5.2. Alzheimer’s disease (AD) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Alzheimer’s disease (AD) Total Market Size in Spain
15.6.2. Alzheimer’s disease (AD) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Alzheimer’s disease (AD) Total Market Size in the United Kingdom
15.7.2. Alzheimer’s disease (AD) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Alzheimer’s disease (AD) Total Market Size in Japan
15.8.3. Alzheimer’s disease (AD) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Alzheimer’s disease (AD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Alzheimer’s disease (AD) market
- To understand the future market competition in the Alzheimer’s disease (AD) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Alzheimer’s disease (AD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Alzheimer’s disease (AD) market
- To understand the future market competition in the Alzheimer’s disease (AD) market
Related Reports:-
1. Alzheimer’s disease (AD) – Epidemiology Forecast to 2030
2. Alzheimer’s disease (AD) – Pipeline Insights, 2020
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/